Article Abstract

Liver segment 2+3 living donation in liver transplantation for colorectal liver metastases

Authors: Svein Dueland, Pål-Dag Line

Abstract

Liver transplantation (LT) was offered to some colorectal cancer (CRC) patients with liver only metastases in the 1990s, however the treatment option was discontinued due to poor overall survival (OS) of 43% at 2 years post- transplant combined with the scarcity of donor organs at that time (1). In 2006 we initiated a pilot study reexamining LT in CRC patients. When the first patients had been observed for 5 years, the Kaplan-Meier estimated OS was 60% (2) and the survival outcome was much better compared to a similar cohort of CRC patients starting first line chemotherapy in the Nordic VII trial (3). LT is also a much better treatment option than any other medical treatment reported in CRC patients having progressive disease on standard chemotherapy including, oxaliplatin, irinotecan, EGDR-antibody and VEGF-antibody (bevacizumab) (4,5).

Article Options

Download Citation